Orthocell Limited Accelerates Asian Commercial Growth Through Thailand Market Expansion
Orthocell Limited (ASX: OCC) has advanced its international commercial strategy by selecting MediTime as the exclusive distributor of Remplir in Thailand, opening access to a nerve repair market valued at approximately US$84 million. The appointment follows regulatory clearance from Thailand's Food and Drug Administration and establishes a strong pathway for commercial sales through an experienced orthopaedic and sports medicine distributor. MediTime's established hospital network, surgeon relationships and clinical education capabilities are expected to support wider adoption of Remplir across the country. The agreement also broadens Orthocell's existing partnership with Device Technologies Group, reinforcing its distribution footprint throughout the Asia-Pacific region. Alongside its international expansion, the company continues to prioritise direct commercial execution in the United States, where Remplir™ is now accessible across approximately 336 hospitals, including 221 military medical centres. Backed by more than AU$48 million in cash and no outstanding debt, Orthocell remains well equipped to fund further commercial expansion and strengthen the global presence of its regenerative medicine portfolio.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Orthocell Limited Accelerates Asian Commercial Growth Through Thailand Market Expansion
Orthocell Limited (ASX: OCC) has advanced its international commercial strategy by selecting MediTime as the exclusive distributor of Remplir in Thailand, opening access to a nerve repair market valued at approximately US$84 million. The appointment follows regulatory clearance from Thailand's Food and Drug Administration and establishes a strong pathway for commercial sales through an experienced orthopaedic and sports medicine distributor. MediTime's established hospital network, surgeon relationships and clinical education capabilities are expected to support wider adoption of Remplir across the country. The agreement also broadens Orthocell's existing partnership with Device Technologies Group, reinforcing its distribution footprint throughout the Asia-Pacific region. Alongside its international expansion, the company continues to prioritise direct commercial execution in the United States, where Remplir™ is now accessible across approximately 336 hospitals, including 221 military medical centres. Backed by more than AU$48 million in cash and no outstanding debt, Orthocell remains well equipped to fund further commercial expansion and strengthen the global presence of its regenerative medicine portfolio.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au